Navigating the New Normal in the Transportation Industry as the Pandemic Continues

Wed, Jun 24, 2020 | By Phil Wilson, Sr. Vice President, Global Logistics and Supply Chain

 

The last few months have been unprecedented in world history. The pandemic that is gripping the world has spared no country, culture or corner, and it has highlighted the gaps in many companies’...

How the Coronavirus Pandemic Is Impacting Global Shipping and Logistics – And How Cryoport Can Help

Tue, Apr 14, 2020 | By Sue Blecman, Vice President - Global Strategic Business Development, Cryoport

As the world experiences unprecedented times caused by the COVID-19 pandemic, Cryoport has been collaborating closely with our clients to help navigate this dynamic environment and to ensure ...

Coronavirus Update: Actions We're Taking

Fri, Mar 20, 2020 | By Cryoport Team

Cryoport continues to proactively monitor the global spread of the COVID-19 virus and to take appropriate mitigating actions. Our team is committed to the health and safety of our employees,...

New FDA Guidelines on Gene Therapy IND Process A Significant Step Forward

Thu, Feb 06, 2020 | By Phil Wilson, Sr. Vice President, Global Logistics and Supply Chain

Recently the FDA’s Center for Biologics Evaluation and Research issued its guidance to the regenerative medicine industry on best practices for submitting an IND application to the FDA for gene...

2019: The Year of Cryoport Milestones

Fri, Dec 06, 2019 | By Cryoport Team

New became the norm at Cryoport this year. The company announced new partnerships, new product lines, and new services seemingly every week. On top of these exciting developments were notable...

Avoiding Catastrophe: Addressing the Supply Chain Risks in Cell and Gene Therapy Development

Thu, Nov 21, 2019 | By Phil Wilson, Sr. Vice President, Global Logistics and Supply Chain

There is no question that the groundbreaking treatments being developed in Cell & Gene Therapy (CGT) are fundamentally changing the way patient care is managed around the world. As with most...

VIDEO: Complying with Critical Regulations: Cryoport’s Chain of Compliance®

Mon, Oct 28, 2019 | By Cryoport Team

Precision medicine requires end-to-end traceability: everything from chain of custody, to chain of condition, to chain of identity. But the fragility of regenerative medicine therapies – and the...

As Cell Therapy Approvals Speed Up, Companies Struggle with Manufacturing Demands

Wed, Oct 09, 2019 | By Jill Robinson, Inside Sales Manager

Early approvals of upcoming cell therapies have moved up manufacturing timelines for many firms in the biotech space. This blaze of approvals has been ignited by positive early clinical trial data...

VIDEO: Cryoport Innovations Support Evolving Needs of Cell and Gene Therapy Industry

Wed, Sep 25, 2019 | By Cryoport Team

The incredible advancements of cell and gene therapies are often surprising to those not intimately familiar with the biopharmaceutical industry. After all, whoever would have imagined that a...

Biostorage: A Critical Component of the Medical Research Development Process

Mon, Sep 16, 2019 | By Nathan Dai, Senior Director, Business Development, Cryoport

The human genome and diseases interact in mysterious ways. Along with external factors, these interactions can affect who gets an illness, how serious it gets, at what rate, how the patient...

When Failure Isn’t an Option, Trust the Supply Chain Partners with a Proven and Successful Track Record

Mon, Aug 26, 2019 | By Ryan Carpentier, Sr. Director, Business Development, Cryoport

The advances in cell and gene therapy over the last few years have been nothing less than remarkable. The amount of resources being poured into their development is reflected in the large number...

Scientific Innovation is Messy. Cryoport is The Reliable Logistics Provider for the Cell and Gene Therapy Trial Process

Wed, Aug 21, 2019 | By Lindsay Belcher, Business Development Director - Northeast, Cryoport

Working for a company that supports cell and gene therapy industry, it’s always exciting to see new treatments finally go to market. Drug companies spend years trying to clear their new medicines...

Cell and Gene Therapy Success Depends on Mastering the New Needs of the Supply Chain: Dispatch from the Shanghai CAR-T Summit

Wed, Aug 14, 2019 | By Ryan Carpentier, Sr. Director, Business Development, Cryoport

Cryoport was honored to be invited to speak at the CAR-T Summit in Shanghai, which gathered the world’s foremost experts on cell and gene therapy. While all presenters highlighted topics that were...

Growing with Our Clients: New Cryoport Innovations Help Support Commercial Gene Therapies and Nearly 400 Clinical Trials

Mon, Jul 08, 2019 | By Kirk Randall, Senior Director, Business Development, Cryoport

We’re proud to provide global support for the first-ever commercial CART-T therapies, produced by our clients Kite (Gilead) and Novartis, as well as bluebird bio’s recently approved gene therapy....

With More Than 200 Cell and Gene INDs on File with FDA by 2020, Challenges Lie Ahead on Path to Approval

Tue, Jun 25, 2019 | By Sue Blecman, Vice President - Global Strategic Business Development, Cryoport

 “By 2025, we predict that the FDA will be approving 10 to 20 cell and gene therapy products a year based on an assessment of the current pipeline and the clinical success rates of these...

Cryoport Rings Nasdaq Closing Bell

Tue, Jun 11, 2019 | By Cryoport Team

This Monday, June 10 was a momentous day for our company: Members of the Cryoport team led the closing bell ceremony at Nasdaq, located in Times Square in New York City. Cryoport stock (CYRX)...

As the Regenerative Medicine Industry Grows, A Complete Support System Is More Critical Than Ever

Wed, May 29, 2019 | By Tom Heinzen, VP, Corporate Development & Investor Relations, Cryoport

The regenerative medicine sector has grown significantly in the past few years, and it’s showing no signs of slowing down.

Learn About Cryoport’s Latest Innovations at the 2019 World Advanced Therapies and Regenerative Medicine Congress and Expo in London

Wed, May 08, 2019 | By Cryoport Team

Cryoport is excited to be a Platinum Sponsor of the 2019 World Advanced Therapies and Regenerative Medicine Congress and Expo in London on May 15-17.

Unpacking the Physics of Cryoport’s Certified, Cool 2-8°C Shipper for Fresh Biospecimen Transportation

Tue, May 07, 2019 | By Nathan Dai, Senior Director, Business Development, Cryoport

There are mainly two types of cooling mechanisms used in the 2-8°C logistics process for biospecimen or drug substances, and they operate on different physics principles.

What’s Next For Regenerative Medicine: Regulations—Lots of Regulations

Wed, Apr 10, 2019 | By Cryoport Team

Technology often evolves faster than laws and regulations can keep up, and the field of regenerative medicine is evolving in the same way. 

Can you Afford to Not Consider the Importance of Informatics in Your Global Temperature Controlled Supply Chain?

Fri, Apr 05, 2019 | By Soren H. Knudsen, Commercial Director, EMEA, Cryoport

The number of clinical trials is increasing: There are more than 275,000 registered on clinicaltrials.gov, a 26 percent increase from the year 2000.

Risk Mitigation in Clinical Trials

Tue, Mar 19, 2019 | By Ryan Carpentier, Sr. Director, Business Development, Cryoport

In 2016, Congress passed the 21st Century Cures Act.  One of the more important aspects of the Act was to expedite the approval process for new drugs and medical devices.  This Act has been a...

Why Evaporative Cooling Shippers Are Not Optimal for Pharmaceutical Applications in the 2-8°C Range

Wed, Jan 23, 2019 | By Nathan Dai, Senior Director, Business Development, Cryoport

Evaporative cooling uses evaporation from a pocket of fluid to achieve cooling inside a shipping container, often targeting the 2-8°C range. Although it might be useful for situations with less...

The Critical Need for the End to End Data Flows for Regenerative Therapies

Thu, Nov 08, 2018 | By Tom Heinzen, VP, Corporate Development & Investor Relations, Cryoport

The global commercial approval of the first CAR-T therapies (Kymriah® and Yescarta®) has intensified the need for the clear and uninterrupted flow of data from before the patient is ever treated...

Beyond Logistics – What’s Needed for Successful Support of Clinical Trials and Commercialization in Regenerative Medicine?

Wed, Oct 31, 2018 | By Sue Blecman, Vice President - Global Strategic Business Development, Cryoport

The tedious process of vendor selection for Clinical Trials, Commercialization Planning and Launch in Regenerative Medicine can be daunting, let alone having to think about the Support necessary...